KAKAKU.COM
26.6.2024 15:01:31 CEST | Business Wire | Press release
Tabelog*2, one of Japan’s largest restaurant search and reservation sites, has launched an online reservation service for visitors to Japan, which supports English, Chinese (Simplified and Traditional) and Korean. With reservations available at over 35,000 restaurants, it is the largest service of its kind in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626189960/en/
Reservation Flow (Graphic: Business Wire)
*1As of June 26, 2024, based on internal research. Largest restaurant reservation service (instant reservations) for visitors to Japan
*2Tabelog is operated by Kakaku.com, Inc. one of Japan’s leading Internet companies.
Tabelog’s online reservation service for overseas visitors
To offer a more convenient way to find and reserve restaurants for the growing number of visitors to Japan, we have launched an online restaurant reservation service where reservations can be made in English, Chinese (Traditional and Simplified), and Korean.
*According to the Japan National Tourism Organization, the number of visitors to Japan is expected to exceed 3 million in May 2024 (up 60% from the previous year).
Features of Tabelog’s service are as follows:
- Search for restaurants in Japan by specifying a location, cuisine, budget, and the date and time you want to make a reservation.
- Select a restaurant based on detailed information about the restaurant, including menu, photos, and reviews posted by Japanese users.
-
Check reservation availability using the calendar function and make online reservations directly on Tabelog.
*Online reservations are currently only available for set menus and require credit card registration. In addition, there is a system usage fee of 440 yen (incl. tax) per person per reservation.
“Japan is currently the destination of choice for travelers from around the world, and many of them want to experience Japan’s food culture. However, there is still a shortage of restaurants equipped to communicate with and take reservations from overseas visitors leading to a situation where only a handful of well-known restaurants are attracting visitors to Japan,” said Taku Kounoike, Head of Tabelog. “As a Japanese gourmet media, we want to support travelers in experiencing the deeper charm of Japan, by showcasing a wide range of excellent restaurants across the country, and by providing a service that enables users to make online reservations. We sincerely hope that your travel experience in Japan will become more fulfilling than ever before.”
Links to the different language versions of Tabelog:
- English: https://tabelog.com/en/
- Simplified Chinese: https://tabelog.com/cn/
- Traditional Chinese: https://tabelog.com/tw/
- Korean: https://tabelog.com/kr/
*Ongoing modifications and improvements to the site may result in changes to the user interface and performance.
About Tabelog
Tabelog provides information on almost all restaurants in Japan, and users can choose restaurants catering to their specific preferences, based on information provided by the restaurants themselves, as well as reviews and photos posted by users. The service receives high marks from users for offering comprehensive information about restaurants and a highly convenient user interface. As of March 2024, it has become one of Japan’s largest restaurant search and reservation services, with approximately 93.5 million monthly users.
About Kakaku.com, Inc. (https://corporate.kakaku.com/?lang=en)
Established in 1997, Kakaku.com, Inc. (TOKYO:2371) is a Japanese internet company operating various web services, including the purchasing support site "Kakaku.com", the restaurant search and reservation service "Tabelog", and the comprehensive job search service "Kyujin Box". In April 2024, the company launched "Jobcube", a comprehensive search site for jobseekers, in the United States.
Service Overview: https://corporate.kakaku.com/company/service/?lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626189960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom